Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

A Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (Blast Successor Trial)

This study is designed to confirm the efficacy, safety, and tolerability of blinatumomab in patients with MRD of B- precursor ALL in complete hematological remission including patients with relapse after SCT. The study aims to expand experience generated in previous trials in patients with MRD positive ALL with a focus on additional specific questions.

Study Overview

• Status: Completed
• Conditions: ALL, Recurrent, Adult
• Intervention / Treatment: Drug: Blinatumomab

Detailed Description

Transfer of patients to alloHSCT after one cycle or after a subsequent cycle is considered as per protocol discontinuation and as premature treatment discontinuation.

In case of hematological or extramedullary relapse, the study treatment will be permanently discontinued.

There will be a safety follow-up visit at 30 days after end of the last infusion. There will be efficacy follow-up until 18 months after treatment start. In patients scheduled for SCT the 30-day safety-visit may be performed at the latest time point possible before initiation of subsequent treatment.

• Study Type: Interventional
• Enrollment (Actual): 83
• Phase: Phase 2

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany
    • Charite - Campus Benjamin Franklin
  • Dresden, Germany
    • Uniklinik Dresden
  • Düsseldorf, Germany
    • Uniklinik Düsseldorf
  • Essen, Germany
    • Univeristätsklinikum Essen
  • Freiburg, Germany
    • Universitätsklinikum Freiburg
  • Göttingen, Germany
    • Universitätsmedizin Göttingen
  • Hamburg, Germany
    • Uniklinik Hamburg Eppendorf
  • Hannover, Germany
    • Medizinische Hochschule Hannover
  • Heidelberg, Germany
    • Uniklinik Heidelberg
  • Kiel, Germany
    • UKSH-Kiel
  • Leipzig, Germany
    • Universitätsklinik Leipzig
  • Mannheim, Germany
    • Klinikum Mannheim
  • Marburg, Germany
    • Universitätsklinkum Gießen und Marburg
  • München, Germany
    • Klinikum Großhadern
  • Münster, Germany
    • Uniklinik Münster
  • Nürnberg, Germany
    • Klinikum Nürnberg Nord
  • Regensburg, Germany
    • Uniklinik Regensburg
  • Stuttgart, Germany
    • Robert - Bosch - Krankenhaus
  • Tübingen, Germany
    • Universitätsklinik Tübingen
  • Ulm, Germany
    • Universitätsklinkum Ulm
  • Würzburg, Germany
    • Uniklinik Würzburg
  • Hessen
    • Frankfurt (Main), Hessen, Germany, 60590
      • University Hospital of Frankfurt (Main)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients with CD19 positive B-precursor ALL in complete hematological remission defined as less than 5% blasts in bone marrow after at least three intense chemotherapy blocks (e.g., GMALL induction I-II/consolidation I).

2. Presence of minimal residual disease (MRD) after an interval of at least 8 days from last systemic chemo-therapy

   • at a level of ≥10-4 - <10-3 (molecular failure or molecular relapse) in an assay with a minimum sensitivity of 10-4 documented after an interval of at least 2 weeks from last systemic chemotherapy OR

   • at levels below 10-4 documented after an interval of at least 2 weeks from last systemic chemotherapy:

     • Positive <10-4, non quantifiable (MolNE1) OR
     • Positive <10-4 (MolNE2) OR
   • Presence of minimal residual disease (MRD), non quantifiable (MolNE3).
3. For evaluation of MRD patients must have at least one molecular marker based on individual rearrangements of immunoglobulin, TCR-genes or other suitable genes evaluated by the reference laboratory of the trial

4. Bone marrow function as defined below:

   • ANC (Neutrophils) >= 1,000/µL
   • Platelets >= 50,000/µL (transfusion permitted)
   • HB level >= 9g/dl (transfusion permitted)

5. Renal and hepatic function as defined below:

   • AST (GOT), ALT (GPT), and AP < 5 x upper limit of normal (ULN)
   • Total bilirubin < 1.5 x ULN (unless related to Gilbert's Meulengracht disease)
   • Creatinine < 1.5x ULN
   • Creatinine clearance >= 60 mL/min (e.g. calculated according Cockroft&Gault)
6. Negative HIV test, negative hepatitis B (HbsAg) and hepatitis C virus (anti-HCV) test
7. Negative pregnancy test in women of childbearing potential
8. ECOG Performance Status 0 or 1
9. Age >=18 years
10. Ability to understand and willingness to sign a written informed consent
11. Signed and dated written informed consent is available
12. Participation in the registry of the German Multicenter Study Group for Adult ALL (GMALL)

Exclusion Criteria:

1. Ph/BCR-ABL positive ALL
2. Presence of circulating blasts or current extramedullary involvement by ALL
3. History or presence of clinically relevant CNS pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome or psychosis)
4. Current detection of ALL blast cells in cerebro-spinal fluid
5. History of or active relevant autoimmune disease
6. Systemic cancer chemotherapy within 2 weeks prior to study treatment (except for intrathecal prophylaxis)
7. Radiotherapy within 4 weeks prior to study treatment
8. Live vaccination within 2 weeks before the start of study treatment
9. Autologous hematopoietic stem cell transplantation (SCT) within six weeks prior to study treatment
10. Allogeneic SCT within 12 weeks before the start of study treatment
11. Any active acute Graft-versus-Host Disease (GvHD), grade 2-4 according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment
12. Any systemic therapy against GvHD within 2 weeks before start of study treatment
13. Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to study treatment
14. Treatment with any investigational product within four weeks prior to study treatment
15. Previous treatment with blinatumomab or other anti-CD19-therapy
16. Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation

17. History of malignancy other than ALL diagnosed within 5 years prior to start of protocol-specified therapy with the exception of:

    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated cervical carcinoma in situ without evidence of disease
    • Adequately treated breast ductal carcinoma in situ without evidence of disease
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer
18. Active infection, any other concurrent disease or medical condition that are deemed to interfere with the conduct of the study as judged by the investigator
19. Nursing women
20. Woman of childbearing potential and is not willing to use 2 highly effective methods of contraception while receiving study treatment and for an additional 3 months after the last dose of study treatment.
21. Male who has a female partner of childbearing potential, and is not willing to use 2 highly effective forms of contraception while receiving study treatment and for at least an additional 3 months after the last dose of study treatment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Blinatumomab; Patients will receive four cycles of treatment, unless criteria for treatment discontinuation apply. The duration of one cycle is 6 weeks, including a four week continuous intravenous infusion and a two week infusion free interval, which may be extended by a maximum of 7 days. Patients entered with MRD level <10-4 (non quantifiable/MolNE1, quantifiable/MolNE2) or positive MRD, non quantifiable (MolNE3) will receive up to two cycles of Blinatumomab. Transfer of patients to alloHSCT after one cycle or after subsequent cycles is considered as per protocol discontinuation and as premature treatment discontinuation In case of hematological or extramedullary relapse, the study treatment will be permanently discontinued.

Drug: Blinatumomab; Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed. In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day. Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab.; Other Names: blincyto

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
MRD response after one cycle	Proportion of patients who achieve complete MRD response after one cycle of treatment with blinatumomab in patients with and without prior SCT	after one cycle of treatment (up to 43 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Continuous complete remission	Probability of continuous complete remission (remission duration) at 18 months following initiation of blinatumomab (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	18 months following initiation of blinatumomab
Hematological relapse-free survival	Probability of hematological relapse-free survival rate at 18 months following initiation of blinatumomab (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	18 months following initiation of blinatumomab
Overall survival	Probability of overall survival at 18 months following initiation of blinatumomab (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	18 months following initiation of blinatumomab
Relapse localisations	Frequency of different relapse localisations in proportion to total hematological relapses (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	In Case of Relapse, continuously until End of Follow-Up (up to 18 Months)
Biological evaluation of hematological and extramedullary relapse	Biological evaluation of hematological and extramedullary relapses including CD19 expression (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	In Case of Relapse, continuously until End of Follow-Up (up to 18 Months)
Serious Adverse Event (SAE) incidence	Overall incidence and severity of adverse events in patients with and without prior SCT (CTCAE 4.0) (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	continuously until End of Safety-Follow-Up (up to 26 weeks)
MRD response after two cycles	Proportion of patients who achieve MRD response after one or two cycles of treatment with Blinatumomab (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	after two cycles of treatment (up to 85 days)
complete MRD response after two cycles	Proportion of patients who achieve complete MRD response after two cycles of treatment with blinatumomab in patients with and without prior SCT (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	after two cycles of treatment (up to 85 days)
duration of MRD response	Probability of continuous MRD response and complete MRD response and duration of MRD response at 18 months following initiation of blinatumomab (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	18 months following initiation of blinatumomab
Time to MRD response	Time to MRD response measured by time-point of first achievement (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	MRD determination after each cycle of treatment (up to 24 weeks)
GvHD	Evaluation of GvHD as part of AE documentation and according to Glucksberg Criteria, grade and localisation. (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	until End of Safety-Follow-Up (up to 26 weeks)
treatment related mortality after subsequent SCT	Evaluation of overall survival, remission duration, relapse-free survival and treatment related mortality (at day 100 and later) in patients with SCT in complete remission after blinatumomab (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	after subsequent SCT (at day 100 and later)
treatment related mortality	Evaluation of overall survival, remission duration, relapse-free survival and treatment related mortality in patients without SCT in complete remission after blinatumomab (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	continuously until End of Follow-Up (up to 18 Months)
Quality of Life	Measurement of Quality of Life with EORTC instruments (EORTC QLQ C30 and EQ-5D) at different time-points during treatment (Separate analysis of all outcome parameters in patients with MRD above 10-4, 10-4-10-3 and patients with MRD below 10-4 or non-quantifiable MRD)	until End of Follow-Up (up to 18 Months)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment deviation1	Incidence of dose reductions	until end of treatment (up to 22 weeks)
Treatment deviation2	incidence of treatment interruptions	until end of treatment (up to 22 weeks)
Treatment deviation3	days of interruption	until end of treatment (up to 22 weeks)
Treatment deviation4	withdrawals	until end of treatment (up to 22 weeks)
Treatment deviation5	total delivered dose	until end of treatment (up to 22 weeks)
Treatment deviation6	total days of treatment	until end of treatment (up to 22 weeks)
Treatment deviation7	realisation rate calculated as scheduled total dose/delivered total dose	until end of treatment (up to 22 weeks)
Hospitalisation days	Number of hospitalisation days	until end of treatment (up to 22 weeks)

Collaborators and Investigators

• Sponsor: Goethe University
• Investigators: Principal Investigator: Nicola Goekbuget, MD, GMALL-Study-Group

Publications and helpful links

General Publications

• Gökbuget N, et al . Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA). Blood (2020) 136 (Supplement 1): 39-40.

Helpful Links

• Trial Register of the Kompetenznetz Leukämien, additional trial information

Study record dates

Study Major Dates

• Study Start (Actual): March 15, 2017
• Primary Completion (Actual): August 15, 2021
• Study Completion (Actual): March 10, 2023

Study Registration Dates

• First Submitted: March 13, 2017
• First Submitted That Met QC Criteria: April 5, 2017
• First Posted (Actual): April 12, 2017

Study Record Updates

• Last Update Posted (Actual): March 21, 2023
• Last Update Submitted That Met QC Criteria: March 17, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: ALL; minimal residual disease; blinatumomab; acute lymphoblastic leukemia; MRD positive
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Neoplastic Processes; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Neoplasm, Residual; Antineoplastic Agents; Blinatumomab
• Other Study ID Numbers: GMALL-MOLACT1-BLINA; 2015-000733-76 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No